Adcetris (brentuximab vedotin)
Adcetris (Brentuximab Vedotin) is a targeted antibody-drug conjugate (ADC) used to treat certain types of lymphoma, including classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma (sALCL). It combines a CD30-targeting monoclonal antibody with a potent anticancer agent to selectively identify and destroy cancer cells while minimizing damage to healthy tissues.
Brukinsa (zanubrutinib)
Brukinsa (Zanubrutinib) is an oral targeted therapy used to treat certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and other blood cancers. As a Bruton's tyrosine kinase (BTK) inhibitor, it works by blocking signals that promote the growth and survival of malignant B cells, helping to control disease progression and improve patient outcomes.
Calquence (acalabrutinib)
Calquence (Acalabrutinib) is an oral targeted therapy used to treat certain blood cancers, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). As a Bruton's tyrosine kinase (BTK) inhibitor, it works by blocking signals that promote the growth and survival of malignant B cells, helping to slow disease progression and improve patient outcomes.
Darzalex (Daratumumab)
Disposable Hand Gloves
Hand Gloves are essential protective accessories designed to provide safety, hygiene, and comfort across various medical, industrial, laboratory, and general-use applications. Manufactured from high-quality materials, they offer excellent protection against contamination, chemicals, and physical hazards while ensuring flexibility and a comfortable fit.
Enhertu (Trastuzumab Deruxtecan)
Enhertu (Trastuzumab Deruxtecan) is an advanced antibody-drug conjugate (ADC) used to treat certain HER2-positive and HER2-low cancers, including breast, gastric, and lung cancers. It combines targeted antibody therapy with a potent anticancer agent to selectively attack cancer cells while minimizing damage to healthy tissues.
Erleada (apalutamide)
Erleada (Apalutamide) is an oral targeted therapy used for the treatment of specific forms of prostate cancer. It works by inhibiting androgen receptors, blocking the effects of male hormones that promote the growth and spread of prostate cancer cells, thereby helping to slow disease progression and improve clinical outcomes.
Face Mask
Face Masks are high-quality protective masks designed to provide effective respiratory protection and help reduce exposure to airborne particles, droplets, and contaminants. Widely used in healthcare, pharmaceutical, laboratory, and industrial environments, they offer a comfortable fit while supporting hygiene and safety standards.
Ibrance (palbociclib)
Ibrance (Palbociclib) is an oral targeted therapy used for the treatment of hormone receptor (HR)-positive, HER2-negative breast cancer. It works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), helping to slow the growth and spread of cancer cells while improving treatment outcomes when used in combination with endocrine therapy.
Imbruvica (Ibrutinib)
Imbruvica (Ibrutinib) is an oral targeted therapy used to treat several blood cancers and chronic immune disorders. It works by inhibiting Bruton's tyrosine kinase (BTK), a protein that plays a key role in the growth and survival of certain cancerous B cells, helping to slow disease progression and improve patient outcomes.
Imfinzi (durvalumab)
Imfinzi (Durvalumab) is an advanced immunotherapy medicine used to treat several types of cancer, including lung cancer and biliary tract cancer. As a PD-L1 inhibitor, it helps the body's immune system recognize and attack cancer cells more effectively, providing a targeted approach to cancer treatment.
Jakafi (ruxolitinib)
Jakafi (Ruxolitinib) is an oral targeted therapy used to treat certain blood disorders and immune-related conditions, including myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD). It works by inhibiting Janus kinase (JAK) pathways that contribute to abnormal blood cell production and inflammatory responses.
